China Pharma Holdings, Inc.
CPHI
$1.80
-$0.04-1.96%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -31.27% | 10.91% | -17.05% | -47.25% | -39.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -31.27% | 10.91% | -17.05% | -47.25% | -39.00% |
| Cost of Revenue | -49.63% | -42.65% | -23.35% | -41.91% | -20.47% |
| Gross Profit | 88.51% | 91.43% | 53.07% | -102.78% | -122.81% |
| SG&A Expenses | 10.50% | 156.94% | -0.27% | 8.05% | 9.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.68% | -34.07% | -17.10% | -30.12% | -13.17% |
| Operating Income | 42.16% | 63.97% | 17.19% | -0.97% | -52.11% |
| Income Before Tax | 41.72% | 63.26% | 17.82% | 0.63% | -43.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 41.72% | 63.26% | 17.82% | 0.63% | -43.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 41.72% | 63.26% | 17.82% | 0.63% | -43.76% |
| EBIT | 42.16% | 63.97% | 17.19% | -0.97% | -52.11% |
| EBITDA | 30.03% | 72.31% | -135.49% | -53.06% | -1,177.30% |
| EPS Basic | 73.96% | 81.84% | 66.42% | 68.65% | 78.04% |
| Normalized Basic EPS | 73.97% | 81.84% | 66.42% | 68.64% | 78.04% |
| EPS Diluted | 73.96% | 81.84% | 66.42% | 68.65% | 78.04% |
| Normalized Diluted EPS | 73.97% | 81.84% | 66.42% | 68.64% | 78.04% |
| Average Basic Shares Outstanding | 123.85% | 102.31% | 144.69% | 216.92% | 554.82% |
| Average Diluted Shares Outstanding | 123.85% | 102.31% | 144.69% | 216.92% | 554.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |